Minimal Residual Disease in Myeloma
Advances in minimal residual disease (MRD) assessment technologies, including next-generation flow and sequencing, have revolutionized multiple myeloma treatment, enabling MRD negativity across the disease spectrum. These developments, alongside emerging liquid biopsy-based assays, are enhancing real-time clinical care and informing treatment strategies. Regulatory progress and clinical trials are further validating MRD's role as a surrogate endpoint, promising improved patient outcomes and novel therapeutic approvals.
Reference News
Advances in minimal residual disease (MRD) assessment technologies, including next-generation flow and sequencing, have revolutionized multiple myeloma treatment, enabling MRD negativity across the disease spectrum. These developments, alongside emerging liquid biopsy-based assays, are enhancing real-time clinical care and informing treatment strategies. Regulatory progress and clinical trials are further validating MRD's role as a surrogate endpoint, promising improved patient outcomes and novel therapeutic approvals.